Stallion IndiaQ1 FY27
Stallion India Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹225P/E: 50.9Market Cap: ₹2.6K CrSector: Chemicals & Petrochemicals
Management growth scorecard
Revenue
Category 2
Margin
Category 1
Fundraise
Yes
Order
N/A
Capex
Yes
3 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 2- →The company expects a revenue CAGR of 30-35% over the next three years.
- →With the commissioning of the 10,000 MT R32 plant by December 2026, annual revenue from this plant is projected at ₹500-600 crores starting FY28.
- →The R32 plant will largely add incremental revenue rather than substituting existing sales.
- →Future growth is driven by new product capacities including the helium plant and upcoming HFO plant.
- →Backward integration and higher-value specialty gases are expected to improve EBITDA margins by 3-4% over the medium term.
- →Faster growth may require raising capital (debt and some dilution) to fund multiple plants planned over the next three years.
- →The Bhilwara R32 facility is considered a game changer, transforming and accelerating the company’s growth trajectory post-2026.
- →Volumes are expected to grow steadily as new plants ramp up, e.g., helium sales growing from 5 containers first year to 24 containers annually later.
Margin guidance
Category 1- →Stallion India Fluorochemicals expects a 30-35% revenue CAGR over the next three years.
- →EBITDA margins are projected to improve by about 3-4% over the medium term due to increased contribution from backward integration and higher value specialty gases.
- →The R32 plant commissioning by December 2026 is expected to contribute 500-600 crore INR in annual revenue, largely incremental and not substituting current revenue.
- →The company anticipates EBITDA to increase by 3-4% and PAT margins to improve significantly with the commissioning of new plants.
- →PAT margins for the conventional business are around 10%, expected to rise with newer, higher margin products like R32 (~24% PAT).
- →Faster growth may require capital raising (debt and possible dilution) to support CAPEX and working capital needs, accelerating the timeline.
- →Overall, a positive trajectory is expected with expansion into manufacturing and backward integration enhancing profitability and EPS over the next 3 years.
3 more insights locked — sign up free to unlock
Fundraise plans
Yes- →The company has not finalized any decision on fundraising through capital raising yet.
- →Earlier, they planned to avoid equity dilution and raise only debt for working capital and expansion.
- →Recent internal financial reviews indicate sticking solely to debt or internal accruals would delay growth or lead to very high debt levels.
- →They are now close to considering a mix of equity dilution and debt to support faster growth and meet project timelines.
- →Dilution is not currently decided but is being contemplated as a prudent step alongside debt.
- →Working capital needs are manageable currently without immediate dilution, but faster growth plans might necessitate raising funds.
- →For upcoming projects like the R32 and HFO plants, timely capital infusion is essential, which may require equity or debt.
- →Overall, fundraising (debt and/or equity) is being evaluated with no conclusive commitment yet.
Order book
- →The management clarified that pre-sold capacities or customer contracts have limited enforceability and value; these are more like MOUs without iron-clad, time-bound commitments with penalties.
- →Experienced management does not rely heavily on such pre-sales since they can be subject to price fluctuations and cancellation risks.
- →There are ongoing advanced negotiations for contracts, including with ISRO, but final contracts are yet to be signed as the plants were not ready earlier.
- →The company expects to sell the full capacity of the new R32 plant (10,000 metric tons) largely in the open market rather than just substituting current procurement.
- →Demand visibility is strong based on the company’s experience; historically they imported over 4,000 tons of R32, which has now reduced significantly.
- →Overall, orderbook is planned but not rigidly contracted, with emphasis on market-driven sales after plant commissioning.
Capex plans
Yes- →The company is investing in a 10,000-ton R32 manufacturing facility at Bhilwara with a CAPEX of around ₹350-400 crore, targeting completion by December 2026.
- →An HFO manufacturing plant with a similar CAPEX (~₹350-400 crore) is planned, expected to add 10,000 tons capacity (5,000 + 5,000 tons).
- →The Mambattu facility in Andhra Pradesh will focus on refrigerant de-bulking, blending, and storage, especially HFO blends, improving profitability and logistics efficiency.
- →Backward integration plans include raw material sourcing for AHF and MDC, though the focus next is on the HFO plant.
- →Capital raising via dilution alongside debt is being considered to fund faster growth and multiple simultaneous plant setups over the next three years.
- →The company aims to complete several plants within the next three years to achieve ₹3,000 crore revenue milestones.
How does Stallion India rank vs peers in Chemicals & Petrochemicals?
Pro feature1Stallion India
Rev 2Mar 1
See full Chemicals & Petrochemicals sector rankings
How does Stallion India rank in Chemicals & Petrochemicals?
Compare Stallion India against every Chemicals & Petrochemicals company (Q1 FY27) on revenue, margins and earnings-call signals.